Загрузка...
Elotuzumab for the treatment of multiple myeloma
Elotuzumab is one of the first two monoclonal antibodies that gained FDA approval for the treatment of multiple myeloma (MM). It targets SLAMF7, which is highly expressed in normal plasma and MM cells as well as natural killer (NK) cells. Elotuzumab demonstrated significant anti-myeloma activity in...
Сохранить в:
| Опубликовано в: : | J Hematol Oncol |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4946088/ https://ncbi.nlm.nih.gov/pubmed/27417553 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-016-0284-z |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|